Pelvic Floor Disorders
Also known as: Cystocele, Enterocele, Pelvic prolapse, Rectocele
Methodology & AI Transparency ⓘ
Pelvic Floor Disorders Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: The pelvic floor is a group of muscles and other tissues that form a sling or hammock across the pelvis.
- 2 Real-world patient consensus: Diagnostic registry N92.6: Pelvic Floor Disorders is managed within OB/GYN & PCOS (aka Cystocele).
- 3 Typical cash cost range: Workup highlights for Pelvic Floor Disorders (N92.6): minimally invasive gynecologic in Pelvic Floor Disorders (N92.6: care).
- 4 Top reported side effects / signs: Objective lab/clinical target for Pelvic Floor Disorders: Fasting Insulin & in Pelvic Floor Disorders (N92.6: HbA1c) (Fasting insulin < 8 uIU/mL (N92.6)) and CBC & Serum in Pelvic Floor Disorders (N92.6: Ferritin (heavy bleeding)).
Ask our AI Specialists anything about Pelvic Floor Disorders
What Is Pelvic Floor Disorders?
The pelvic floor is a group of muscles and other tissues that form a sling or hammock across the pelvis. In women, it holds the uterus, bladder, bowel, and other pelvic organs in place so that they can work properly. The pelvic floor can become weak or be injured. The main causes are pregnancy and childbirth. Other causes include being overweight, radiation treatment, surgery, and getting older. Common symptoms include: Feeling heaviness, fullness, pulling, or aching in the vagina. It gets worse by the end of the day or during a bowel movement.
Pathophysiology, Underlying Causes & Clinical Presentation
At the cellular and tissue level in ob/gyn & pcos, Pelvic Floor Disorders (N92.6) involves pelvic peritoneal cytokine in Pelvic Floor Disorders (N92.6: sensitization). Cross-referenced with NIH MeSH (Pelvic Floor Disorders, Pelvic Organ Prolapse), progression correlates with shifts in Fasting Insulin & in Pelvic Floor Disorders (N92.6: HbA1c) (Fasting insulin < 8 uIU/mL (N92.6)).
Common Symptoms & Clinical Signs
- • Feeling heaviness, fullness, pulling, or aching in the vagina. It gets worse by the end of the day or during a bowel movement
- • Seeing or feeling a "bulge" or "something coming out" of the vagina
- • Presentation of Pelvic Floor Disorders (N92.6): severe pelvic cramping [Pelvic Floor Disorders N92.6]
- • Secondary Pelvic Floor Disorders clinical sign: hyperandrogenic acne along in Pelvic Floor Disorders (N92.6: the jawline, hirsutism,)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Pelvic Floor Disorders Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | N92.6 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | PCOS, Endometriosis & Gynecologic Health | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: Fasting Insulin & in Pelvic Floor Disorders (N92.6: HbA1c) | Fasting insulin < 8 uIU/mL (N92.6) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: CBC & Serum in Pelvic Floor Disorders (N92.6: Ferritin (heavy bleeding)) | Ferritin > 50 ng/mL (N92.6) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: LH, FSH & in Pelvic Floor Disorders (N92.6: Prolactin) | Normal ovulatory endocrine axis (N92.6) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Pelvic Floor Disorders
Treatment selection for Pelvic Floor Disorders depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Pelvic Floor Disorders)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Six Decades of Pelvic Exenterative Surgery for Gynaecological: What a 13,434-Participant Study Found PE carries substantial morbidity, while perioperative mortality was approximately 5% overall and 3.7% in post-2005 studies. In vivo (Athens, Greece) • 2026-01-15 • Meta-Analysis | N = 13,434 | 94/100 | PMID 42957251 ↗ |
| New Insights on Responsiveness and thresholds for clinically meaningful changes in worst pain: What a 871-Participant Study Found Based on these results, clinically meaningful changes were defined as a reduction of 4 points for NRS-DYS and 2 points for NRS-NMPP. Fertility and sterility • 2021-02-15 • Phase III Randomized Trial | N = 871 | 93/100 | PMID 33066973 ↗ |
| New Insights on Effect of Pelvic External Beam Radiation Therapy on Bone Mineral Density: A: What a 447-Participant Study Found We did not find sufficient evidence to suggest any detrimental effect of pelvic XRT on the treatment effect from denosumab on percent BMD change, with only an approximately 5% incidence of clinical fractures. International journal of radiation oncology, biology, physics • 2024-05-01 • Phase III Randomized Trial | N = 447 | 93/100 | PMID 37924987 ↗ |
| Should add-back therapy for endometriosis be deferred for optimal results? A significantly smaller number of patients in the immediate add-back group reported hot flushes during the first 12 weeks of treatment compared with the deferred add-back group. British journal of obstetrics and gynaecology • 1996-10-15 • Randomized Controlled Trial | Multi-cohort | 88/100 | PMID 8916982 ↗ |
| New Insights on Extended Versus Limited Pelvic Lymph Node Dissection During Radical Prostatectomy: What a 300-Participant Study Found This RCT confirms that EPLND provides better pathological staging, while differences in early oncological outcomes were not demonstrated. European urology • 2021-05-15 • Phase III Randomized Trial | N = 300 | 87/100 | PMID 33293077 ↗ |
Pelvic Floor Disorders Patient Community & “People Like Me” Threads
Filter Pelvic Floor Disorders community threads and patient logs by age, biological sex, dosage, and treatment duration.